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Extracellular matrix in solid tumors has emerged as a specific, stable, and abundant target for affinity-
guided delivery of anticancer drugs. Here we describe the homing peptide that interacts with the 
C-isoform of Tenascin-C (TNC-C) upregulated in malignant tissues. TNC-C binding PL3 peptide (amino 
acid sequence: AGRGRLVR) was identified by in vitro biopanning on recombinant tnc-c. Besides tnc-
C, PL3 interacts via its C-end Rule (CendR) motif with cell-and tissue penetration receptor neuropilin-1 
(NRP-1). Functionalization of iron oxide nanoworms (NWs) and metallic silver nanoparticles (AgNPs) 
with PL3 peptide increased tropism of systemic nanoparticles towards glioblastoma (GBM) and prostate 
carcinoma xenograft lesions in nude mice (eight and five-fold respectively). Treatment of glioma-
bearing mice with proapoptotic PL3-guided NWs improved the survival of the mice, whereas treatment 
with untargeted particles had no effect. PL3-coated nanoparticles were found to accumulate in TNC-C 
and NRP-1-positive areas in clinical tumor samples, suggesting a translational relevance. The systemic 
tumor-targeting properties and binding of PL3-NPs to the clinical tumor sections, suggest that the 
PL3 peptide may have applications as a targeting moiety for the selective delivery of imaging and 
therapeutic agents to solid tumors.
The microenvironment in solid tumors is shaped by concerted actions of tumor cells and cells in tumor stroma 
(endothelial cells, immune cells, and fibroblasts). All these cells deposit and remodel tumor extracellular matrix 
(ECM) – a complex meshwork of structural proteins and bioactive compounds. In addition to the structural role, 
the tumor ECM modulates invasion and distant spreading of tumor cells, tumor angiogenic status, and immune 
microenvironment, thereby plays a critical role(s) in tumor initiation, progression, and metastasis1. The molecu-
lar composition of tumor ECM reflects its type, origin, and physiological status2. Tumor ECM is rich in compo-
nents expressed in developing and/or regenerating tissues that are typically absent or expressed at a lower level in 
quiescent healthy adult tissues and organs3. Tenascin C (TNC) is an ECM glycoprotein that is upregulated during 
normal tissue repair and in many human malignancies and plays important roles in tumor neovascularization, 
modulation of adhesion, and local and distant motility of malignant cells, and modulation of tumor immune 
status4. Several affinity ligands of TNC have been developed for targeting payloads to solid tumors, such as G11 
single-chain antibody5, aptamers6, FH peptide7, and PL1 peptide8. TNC targeting antibodies are in phase I/II/
III clinical trials as affinity targeting modules for cytotoxic or immunomodulatory payloads for therapy of solid 
tumors including metastatic renal cell carcinoma, metastatic melanoma, pancreatic carcinoma, acute myeloid 
leukemia, sarcoma and breast carcinoma, lung cancer, colorectal cancer, and glioma4. Importantly, malignant 
transformation is not only able to increase the expression of tenascin-C, but also influence its qualitative com-
position by modulating the splicing to result in different proportion of its isoforms. In particular, 91-amino acid 
alternatively spliced type-III homology domain of Tenascin-C FnIII C (TNC-C) has a tumor-restricted expres-
sion pattern5,8,9. The TNC-C is abundant in the glial tumors of the CNS, as well as in various carcinomas10–12. 
Overexpression of TNC-C correlates with tumor grade and is associated with poor prognosis12,13.
Peptides have several advantages over antibodies as tumor-targeting vehicles, including small size (and thus 
straightforward synthesis, eliminating the need for antibody-protein engineering), low immunogenicity, moder-
ate cost, biocompatibility, and low-micromolar affinity range that circumvents the affinity site barrier14–16. Small 
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peptides as targeting elements are particularly relevant in the context of nanomaterials, where even small mole-
cule targeting ligands with weak affinity can through multivalent interactions significantly enhance target-specific 
avidity (by up to 4 orders of magnitude), and thus the affinity of the final material is readily tunable17.
Here we set out to develop peptidic affinity ligands for targeting TNC-C in solid tumors. Using peptide phage 
display, we identified an octameric homing peptide, PL3, that interacts with TNC-C in vitro and in vivo. In addi-
tion, PL3 peptide was able to interact with cell- and tissue penetration receptor NRP-1. Systemic PL3-guided 
nanoparticles accumulated in tumor xenografts implanted in mice. These nanoparticles were useful for tumor 
detection, imaging and served as a tumor-seeking carrier for a proapoptotic peptide anticancer payload. Our 
study suggests applications for PL3-targeted compounds and nanoparticles for improved detection and therapy 
of solid tumors.
Materials and Methods
Materials. Phosphate-buffered saline (PBS) was purchased from Lonza (Verviers, Belgium). K3[Fe(CN)6], 
HCl, isopropanol, Triton-X, Tween-20, CHCl3, MeOH, Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
and dimethylformamide (DMF) were purchased from Sigma-Aldrich (Munich, Germany). Cys-fluorescein 
(FAM)-PL3 and Cys-FAM peptides with 6-aminohexanoic acid spacer were purchased from TAG Copenhagen 
(Denmark). PL3-D(KLAKLAK)2 and D(KLAKLAK)2 peptides were synthesized using Fmoc/t-Bu chemistry on 
a microwave-assisted automated peptide synthesizer (Liberty; CEM Corporation, Matthews, NC, USA). High-
performance liquid chromatography (HPLC) was used to purify the peptides with 0.1% trifluoroacetic acid (TFA) 
in acetonitrile-water mixtures to 90%–95% purity. The peptides were validated by quadrupole time-of-flight 
(Q-TOF) mass spectral analysis18. CF647 amine dye was purchased from Biotium (Hayward, CA, USA).
cell lines and experimental animals. The U87-MG (human glioblastoma, HTB-14) cells, PC3 (prostate 
carcinoma, CRL1435) cells, PPC1 (primary prostate carcinoma-1) cells were purchased from ATCC. Murine 
WT-GBM glioblastoma cells were a kind gift from Gabriele Bergers (UCSF, USA) and P3, P8, P13 stem cell-like, 
P22, NCH421K cells were a kind gift from Rolf Bjerkvig, (University of Bergen, Norway), and M21 melanoma 
cells were the gift of David Cheresh (USA). Cells and tumors were prepared as described previously19–21.
Athymic nude mice (Hsd/Athymic Fox1 nu Harlan) were purchased from Envigo (Netherlands) and main-
tained under standard housing conditions of the Animal Facility of the Institute of Biomedicine and Translational 
Medicine, University of Tartu (Tartu, Estonia). For orthotropic GBM tumor models, we used NCH421K, P13, 
and P3 stem cell-like, WT-GBM cells. The individual GBM cells around 2–3 × 105 in 3 μL PBS were intracranially 
implanted into mice brain 2 mm right and 1 mm anterior to the bregma. U87-MG and PC3 subcutaneous models 
were induced by injecting 2–9 × 106 cells in 100 µl PBS subcutaneously into the right flank of 11–15 week old male 
and female nude mice. All animal experiments were performed in accordance with the procedures approved by 
the Committee of Animal Experimentation of Estonian Ministry of Agriculture, permits #42 and #48.
peptide phage biopanning. For biopanning on recombinant human TNC-C, we used NNK-encoded 
CX7C and X7 peptide T7 phage libraries with diversity ~5 × 108. Throughout our screens, the selected phages 
were amplified following plate amplification protocol22. The 1st and 4th rounds of biopanning were performed 
on TNC-C immobilized on Costar 96-Well ELISA plate (#3590, Corning Life Sciences, Tewksbury, MA, USA). 
Briefly, the multiwell plates were coated with 20 µg/ml recombinant TNC-C in 100 µl of PBS overnight at 4 °C, 
followed by blocking with 1% bovine serum albumin (BSA) in PBS overnight at 4 °C. The phage library (5 × 108 
pfu in 100 µl of PBS-BSA) was incubated overnight at 4 °C, followed by 6 washes with PBS containing 1% BSA and 
0.1% Tween-20 (washing buffer) to remove background phages, and by phage rescue and amplification in E. coli 
strain BLT5403 (Novagen, EMD Biosciences, MA, USA)8. The subsequent rounds of selection were performed on 
Ni-NTA Magnetic Agarose Beads (QIAGEN, Hilden, Germany) coated with His-6X tagged TNC-C (30 µg/10 µl 
beads) at room temperature for 1 h in 400 µl of PBS. The TNC-C beads were washed 3 times with washing buffer, 
followed by incubation with phages in (5 × 108 pfu in 100 µl in washing buffer) at room temperature for 1 h. The 
background phages were removed by rinsing 6 times with washing buffer, and the bound phages were eluted with 
1 ml of PBS containing 500 mM Imidazole and 0.1% NP40.
The eluted phages were titered and amplified for a next round of selection. After 5 rounds of selection, 
peptide-encoding DNA from a set of 48 phage clones was subjected to Sanger sequencing of peptide-encoding 
phage DNA18,22. For cell-free binding studies with individual phage clones were incubated with Ni-NTA magnetic 
beads coated with hexahistidine-tagged TNC-C as above. RPARPAR phage binding to NRP-1-coated beads was 
used as a positive control23. Phage clones displaying heptaglycine peptide (GGGGGGG, G7), or insertless phage 
clones were used as negative controls.
Fluorescence polarization assay. Fluorescence anisotropy (FA) saturation binding experiments were 
set up as described previously24,25. The experiments were carried out in Dulbecco’s Phosphate Buffer Saline 
(Sigma-Aldrrich, Cat# D8662) with the addition of 0.1% Pluronic F-127 (Sigma-Aldrrich, Cat#P2443) in a final 
volume of 100 μl using 96‐well half area, flat‐bottom polystyrene NBS multiwell plates (Corning, Cat# 3686). The 
different concentrations of proteins (0–112 µM NRP1 or 0–275 µM TNC-C) were added to a fixed concentration 
(0.66 µM) of FAM-Cys-PL3 fluorescent ligand (KJ Ross-Petersen aps). The total and non‐specific binding was 
measured in the absence or in the presence of a 500 µM Biotin-Ahx-PL3 (KJ Ross-Petersen aps) respectively, 
after 24 h incubation at 25 °C in the dark, sealed with moisture barrier (4Titude, Cat# 4ti-0516/96). The con-
centration of fluorescent ligand and proteins in-stock solutions was determined by absorbance (for FAM-PL3 
ε495  =  75000 M−1 cm−1, for NRP1 ε280  =  67630 M−1 cm−1 and TNC-C ε280  =  8480 M−1 cm−1 were used). The 
measurements were performed at 25 °C on a Synergy NEO (BioTek) microplate reader using an optical mod-
ule with an excitation filter at 485 nm (slit 20 nm), emission filter at 528 nm (slit 20 nm) and polarizing beam 
3Scientific RepoRtS |         (2020) 10:5809  | https://doi.org/10.1038/s41598-020-62760-y
www.nature.com/scientificreportswww.nature.com/scientificreports/
splitting for dual-channel detection. Dual emission detection mode allows simultaneous recording of intensities 
that are parallel (I||) and perpendicular (I⊥) to the plane of excitation light. Sensitivities of channels (G factor) 
were calibrated with gain adjustment of the photomultiplier tubes using fluorescein (1 µM reference solution, 
Lambert Instruments) as a standard. The fluorescence anisotropy values were calculated as parameters FA from 
the equation X: FA = (I||−G·I⊥)/(I|| + 2·I⊥). The binding affinity was estimated by global fitting of the data as in25. 
This simultaneous fitting of total and non‐specific binding data takes into account the ligand depletion by both 
binding processes.
Nanoparticle synthesis and functionalization. The iron oxide nanoworms (NWs) were prepared 
according to a published protocol by8,26,27. The aminated NWs were PEGylated using maleimide-5K-PEG-NH. 
Peptides were coupled to NWs through a thioether bond between the thiol group of a cysteine residue added to 
the N-terminus of the peptide. The concentration of the NWs was determined by measuring the absorbance of 
NWs at 400 nm with a NanoDrop 2000c spectrophotometer (Thermo Scientific)8,27. Silver nanoparticles (AgNPs) 
were synthesized and functionalized as described28, CF647- N-hydroxysuccinimide-dye (NHS-dye) was con-
jugated to the PEG terminal amine groups, and biotinylated peptides were coated on the NeutrAvidin (NA) on 
the surface of the AgNPs. Transmission electron microscopy (TEM, Tecnai 10, Philips, Netherlands) was used 
to image the NPs and DLS (Zetasizer Nano ZS, Malvern Instruments, UK) was used to assess the zeta potential, 
polydispersity, and size of nanoparticles.
In vivo play-off phage auditioning. In vivo play-off was used for internally controlled and competitive 
systemic phage homing studies in mice bearing tumor xenografts. Phages displaying the candidate TNC-C 
binding peptides and control peptides were individually amplified and purified by precipitation with PEG-8000 
(Sigma-Aldrich, St. Louis, MO, USA), followed by CsCl2 gradient ultracentrifugation and dialysis. The phages 
were pooled at equimolar representation (Table 1 for details) and injected iv at 1 × 1010 pfu (in 200 µl PBS) 
in tumor-bearing mice, circulated for 2 h, followed by anesthesia and intracardial perfusion with DMEM. The 
tumors and organs were collected in lysogeny broth (LB) medium containing 1% NP40, and the tissues were 
homogenized using a hand-held homogenizer. Phages in the tissue lysate were amplified in E.coli, purified by 
precipitation with PEG-8000, and DNA was extracted using a DNA extraction kit (High Pure PCR Template 
Preparation Kit; Roche, Basel, Switzerland). Next-generation sequencing of phage genomic DNA with Ion 
Torrent system (Thermo Fisher Scientific, Waltham, MA, USA) was used to evaluate the representation of each 
peptide-phage in the input mixture, in tumors and control organs. The FASTQ data from Ion Torrent were pro-
cessed using a custom python script that identified the barcodes, constant flanking residues, and extracted the 
reads of the correct length.
In vivo fluorescence imaging with the IVIS Spectrum system. PL3 peptide tumor homing in mice 
bearing U87-MG xenografts was assessed by in vivo fluorescence imaging using the IVIS Spectrum imaging sys-
tem (PerkinElmer, Waltham, MA). AgNPs coated with CF647 dye-labeled neutravidin were functionalized with 
biotinylated PL3 peptide (PL3-AgNP) or biotin (AgNP). AgNPs were iv injected, and the mice were placed in a 
dark chamber under isoflurane anesthesia for imaging (parameters: specific excitation filter, 650 nm; emission 
filter, 665 nm; auto exposure time; binning, medium; the field of view, 12; f/stop, 2). The images were captured at 
pre-injection (0 h) and 5 h post-injection. The signal was expressed in total Radiant Efficiency [p/s]/[µW/cm²]. 
Phage-displayed peptides in the“play-off ” cocktail
Representation of phage in tumors or in control brain tissue 
(fold G7 control phage)
WT-
GBM P3 SCL P13 U87-MG PC3
Norm. 
brain




AGVGRLRRAKLAAALE Clone-1 2.3 0.9 0.9 1.0 1.4 0.2
CRGVLRRAKLAAALE Clone-2 1.6 0.4 0.4 0.7 0.9 0.1
AVRGRLRVAKLAAALE Clone-3 1.3 0.6 0.6 0.8 1.0 0.1
CSRRGILRAKPAAALE Clone-4 1.5 0.9 0.8 1.1 1.2 0.1
AGRGRLVRAKLAAALE Clone-5 23.9 0.4 0.1 0.2 0.3 0.0
VGRVRFSRKLAAALE Clone-30 2.5 0.4 0.5 0.7 1.2 0.1
RRLVRVA Clone-35 1.4 0.3 0.4 0.6 0.9 0.1
RGRLVRA Clone-45 3 0.3 0.4 0.8 1.8 0.1




AGRGRLVR Modified clone-5 (PL3) 24.1 2.1 4.7 2.1 3.9 0.4
CAGRGRLVRC Modified clone-5 0.9 0.2 0.4 0.1 0.4 0.0
RGRLVRAK Modified clone-5 23.8 0.3 0.1 0.5 3.0 0.2
Table 1. In vivo play-off audition of TNC-C-selected phages. An equimolar mix of TNC-C-selected phages 
was i.v. injected in mice bearing WT-GBM, P3 stem cell-like, P13, and U87-MG glioblastoma, or PC3 prostate 
carcinoma xenografts at 1 × 1010 pfu/mouse. After 2 h circulation, background phages were removed by 
perfusion. Representation of each phage in tumor tissue or in normal brain was assessed by Ion-Torrent high-
throughput sequencing. In the tumor tissue, clone 5-derivative phage PL3 (AGRGRLVR) showed the highest 
representation across tumor models tested. The data represent mean; N = 3 mice for each model.
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The regions of interest (ROIs) were drawn for the whole tumor after tissue background correction, and radiant 
efficiency signal was quantitated. An automated spectral unmixing algorithm was used, images were analyzed by 
using Living Image 4.4 software (Caliper Life Sciences, Hopkinton, MA). Three animals per experimental group 
were analyzed. For the receptor blocking studies, PL3-AgNP injection was preceded by systemic pre-injection of 
blocking TNC-C and/or NRP1 antibodies (30 µg/mouse) 15 min prior to injection of the AgNPs.
Cell binding and internalization experiments. U87-MG, PPC1, and M21 cells cultured on glass covers-
lips were incubated with CF555-labeled AgNPs at 37 °C for 1 h, followed by washing with medium to remove back-
ground AgNPs. Etching solution freshly diluted from 0.2 M stock solutions of Na2S2O3 and K3Fe(CN)6 to 10 mM 
working concentration in PBS was applied to cells for 3 min, followed by PBS washes. The cells on coverslips were 
fixed with −20 °C methanol for 1 min. The cell membrane was visualized by staining with Alexa Fluor 488-labeled 
wheat germ agglutinin (WGA) at 1:1000 at RT for 1 h. Nuclei were stained with 4′,6-diamidino-2-phenylindole 
(DAPI, Molecular Probes) at 1 µg/mL. Fluoromount-G (Electron Microscopy Sciences) medium was used to 
mount the coverslips on microscope slides for confocal imaging.
tumor-targeted delivery and biodistribution studies. FAM-labeled PL3 peptide coupled NWs or con-
trol FAM-NWs (7.5 mg /kg) in PBS were injected into the tail vein of mice bearing subcutaneous U87-MG, PC3, 
and orthotropic WT-GBM tumors. After 5 h circulation, the mice were perfused with 20 ml PBS/DMEM under 
deep anesthesia and tumors and control organs were collected. Tissues were ex vivo imaged using an Illuminatool 
Bright Light System LT-9900 (Lightools Research, Encinitas, CA, USA) and snap-frozen. The tissues were cry-
osectioned at 8–10 µm and mounted on a Superfrost plus slides. The sections were equilibrated at RT and fixed 
with 4% paraformaldehyde at RT for 20 min, or with methanol at −20 °C for 1 min. The immunostaining was 
performed with the following primary antibodies; rabbit anti-fluorescein IgG fragment (cat. no. A889, Thermo 
Fisher Scientific, MA, USA), rat anti-mouse CD31 (BD Biosciences, CA, USA), and in-house prepared CF647 
or CF546-labeled single-chain ScFV G11. Secondary antibodies were Alexa 488 goat anti-rabbit IgG, Alexa 647 
goat anti-rat IgG, and Alexa 546 goat anti-mouse IgG (all Invitrogen, CA, USA). Nuclei were counterstained 
with DAPI at 1 μg/ml. The coverslips were mounted on glass slides using Fluoromount-G (Electron Microscopy 
Sciences, PA, USA), imaged using confocal microscopy (Olympus FV1200MPE, Hamburg, Germany), and ana-
lyzed using the FV10 –ASW4.2 viewer, Imaris, and Fiji ImageJ software tools8,27.
experimental therapy. Tumors were induced by s.c. injection of 8 ×106 U87-MG cells into the 
right dorsal flank of 18–20-week old male nude mice (weight 38 ± 5 g). When the tumor volume reached 
100 ± 20 mm3, the mice were assigned randomly into 4 groups (N = 6 per group). For experimental therapy, 
the mice were treated with i.v. injections of 100 μl of PBS, FAM-D[KLAKLAK]2-NWs, FAM-PL3-NWs, and 
FAM-PL3-D[KLAKLAK]2-NWs every other day for 10 injections. Every 2 days the body weight and animal 
well-being (behavior, appearance, grooming) were assessed, and the tumor volume was measured using a digital 
caliper. The tumor volume was calculated with this formula: Volume (V) (mm3) = [length × (width)2]/2. The 
study was terminated when the tumor volume reached 2000 mm3 (or >20% body weight). At the end of the study, 
the mice were perfused, followed by tumors, and control organs were excised and snap-frozen for histological 
studies. Tumor volume, Kaplan–Meier survival and body weight curves were calculated for each group using the 
GraphPad Prism 6 software with p values <0.05 were considered significant.
overlay assay on clinical tumor samples. All methods for the use of human samples were carried out 
in accordance with relevant guidelines and regulations. The collection and use of human samples was approved 
by the Research Ethics Committee of the University of Tartu, Estonia (permit #243/T-27). Freshly excised human 
samples were obtained during surgeries from Department of Neurosurgery, Tartu University Hospital, Estonia. 
The informed consent was obtained from all patients. The tissue samples were snap-frozen in liquid nitrogen, cry-
osectioned at 10 μm, fixed with methanol, and permeabilized with PBST buffer (1X Phosphate-Buffered Saline, 
0.1% Tween 20), followed by incubation with blocking buffer containing 5% BSA, 5% goat serum, 5% FBS in 
PBST. For overlay, the sections were incubated with 20 μg/slide PL3-NW and NW overnight at 4 °C. The sections 
were washed and blocked with a blocking buffer, followed by immunostaining using rabbit anti-fluorescein pri-
mary antibodies and detection with the Alexa-488 anti-rabbit and mouse anti-TNC-C antibody and detection 
with the 647 goat anti-mouse IgG8.
Statistical analysis. Prism 6 software was used for statistical analysis. The results were presented as mean 
with error bars indicating ±SEM. For a comparison of 2 groups, we used a comparison using an unpaired t-test 
and multiple groups ANOVA test. P < 0.05 was considered significant and P-values were indicted as follows: 
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and ****P ≤ 0.0001.
Results
Identification of a TNC-C binding peptide. TNC-C was expressed in E. coli and purified using affinity 
chromatography on Ni-NTA matrix (Fig. S1). For identification of TNC-C–interacting peptides, 5-round biopan-
ning with of T7 CX7C peptide phage libraries was performed, using as the target his-tagged TNC-C coated on 
polystyrene multiwell plates in rounds 1 and 4, and TNC-C immobilized on Ni-NTA magnetic beads in rounds 
2, 3 and 5 (Fig. S2). Selection on TNC-C in multiwell plates was included to avoid enrichment for histidine-con-
taining peptides on the Ni-NTA beads. By round 5, ~1000-fold enrichment in the binding of the selected phage 
pool to TNC-C was observed (Fig. 1A). Sanger sequencing of a peptide-encoding region of the genome of 38 
random phage clones from round 4 demonstrated a shift away from original cyclic CX7C library configuration 
due to frameshifts in the peptide-encoding region (Table. S1) and overrepresentation of the linear peptides con-
taining the following motifs: RGRLXR (7 repeats), RGRLR (18 repeats), and RLXR (12 repeats)(Table S1). Next, 
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we created a panel of T7 phage clones displaying peptides derived from the phage clone 5 (Table S1) that contains 
the longest enriched motif, RGRLXR, and characterized their binding to TNC-C (Fig. S3).
For evaluation of systemic tumor homing of the candidate TNC-C-targeting peptides, we used in vivo phage 
play-off auditioning22. Tumor-bearing mice were injected i.v. with a phage pool of equally represented candidate 
TNC-C binding and control phages, followed by circulation, perfusion, and assessment of representation of phage 
clones in malignant tissue (4 glioma models and 1 prostate cancer model) and in normal brain tissue (Table 1). 
We found that a T7 clone displaying AGRGRLVR octapeptide was overrepresented in tumor tissue across models 
tested. In the following studies, we focused on AGRGRLVR peptide that we codenamed PL3.
Fluorescent anisotropy is widely used for solution-based characterization of interaction of small fluorescent 
ligands with larger partners and is thus well suited for studies of binding of FAM-Cys-PL3 (mW:1.46 kDa) to 
NRP1 b1b2 domain (mW:37.8 kD) and TNC-C (mW: 12.3 kDa). Binding of FAM-PL3 to both targets was sat-
urable, although at different levels, likely due to different rotational mobility of bound ligand due to the ~3 fold 
difference in molecular weight of TNC-C and NRP-1. The Kd values were obtained by global fitting data to a 
binding isotherm, assuming single binding site with ligand depletion25. For PL3/NRP-1 interaction, the Kd was 
1.1 ± 0.2 μM (Fig. 1D) - similar to published Kd values for the C-terminal arginine-displaying CendR peptide 
with the b1b2 domain of NRP-129. For PL3/TNC-C, the fluorescent anisotropy assay and calculations yielded Kd 
of 51 ± 19 μM (Fig. 1C). However, we observed dequenching of FAM signal after tryptic digestion of PL3/TNC-C 
complex (Fig. S17), suggesting involvement of more than one binding sites and thus, a lower Kd. The detailed 
mode of interaction of PL3 with TNC-C is a subject for follow-up studies.
PL3 peptide interacts with recombinant TNC-C and NRP-1 and is taken up by cultured tumor 
cells. We next studied the binding of alanine-substituted PL3-derivative peptide-phages to determine the 
amino acids important for peptide binding. The substitution of arginine or leucine residues in PL3 peptide 
resulted in decreased binding to recombinant TNC-C (Fig. 1B). In contrast, alanine substitutions of glycine 
and valine had a minimal effect. In contrast to robust interaction with TNC-C, the PL3 phage did not bind to 
Figure 1. Identification and cell-free binding of PL3 peptide. (A) Selection of CX7C T7 phage library on 
immobilized TNC-C resulted in ~1000-fold increase in phage binding in round 5. Binding is expressed fold 
heptaglycine (G7) control phage. (B) Structural requirements for binding of PL3 peptide to TNC-C and NRP-1. 
T7-displayed PL3 peptide AGRGRLVR was subjected to alanine scanning mutagenesis (alanine substitutions 
indicated by underlined bold). Phage binding to TNC-C and NRP-1 is expressed as percent binding of parental 
PL3 phage. Values represent mean ± standard deviation from 3 independent experiments. (C,D) Saturation 
curve for the binding of FAM-Cys-PL3 to TNC-C and NRP1. FAM-Cys-PL3 (0.66 µM) was incubated with 
different concentrations of proteins in the absence (total binding, open circles) or presence (nonspecific 
binding, filled circles) of 0.5 mM Biotin-Ahx-PL3. After a 24 h incubation at 25 °C, FA values were calculated 
according to FA = (I | | − G·I⊥)/ (I | | + 2·I⊥) and fitted globally. The data represents the mean ± the standard 
deviation of 3 independent experiments.
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fibronectin EDB-domain, a protein with similar size and negative surface charge as TNC-C (Fig. S4). PL3 peptide 
includes a C-terminal RXXR motif known to target NRP-1 cell and tissue penetration receptor23 overexpressed in 
most solid tumors. PL-3 phage bound to recombinant b1b2 domain of NRP-1 ~200 fold more than heptaglycine 
control phage (Fig. 1B). Interaction with NRP-1 was dependent on the presence of C-terminal arginine, as the 
phage with terminal R > A PL3-derivative peptide showed a dramatically reduced binding (Fig. 1B).
Many cultured tumor cell lines overexpress NRP-1 and internalize peptides with active CendR motif. We next 
studied the uptake of CF555-labeled PL3-AgNPs in TNC-C and NRP-1-positive U87-MG glioma cells, NRP-
1-positive PPC1 prostate carcinoma cells, and in TNC-C and NRP-1-negative M21 melanoma cells (Fig. S15). 
The dye-labeled AgNP cores are well suited for fluorescence imaging as the AgNP increases the brightness of 
the surface-bound dye by about an order of magnitude by plasmonic enhancement. The AgNPs labeled with 
CF647 dye were coated with neutravidin (NA) and PEGylated as described previously, creating a stable col-
loid ready for coating with biotinylated peptides. The TEM and DLS showed that particles had an average size 
of 66.9 ± 27.6 nm, and zeta potential of −5.09 ± 0.19 mV in PBS (Fig. S5). After 1 h incubation with U87-MG 
and PPC1 cells, PL3-AgNPs were robustly endocytosed with perinuclear accumulation, whereas control nan-
oparticles showed only a background binding (Fig. 2A,B). In contrast, NRP-1-negative M21 cells showed a low 
background-like uptake with both PL3 and control AgNPs. Extracellular AgNPs can be removed by treatment 
Figure 2. PL3-functionalized AgNPs are taken up in NRP-1-positive PPC1 cells. PL3-AgNPs, or control AgNP 
particles (37 µL of 100 O.D. stock solution) labeled with CF555 fluorophore were incubated with PPC1 prostate 
carcinoma, U87-MG glioma, or M21 melanoma cells for 1 h, washed, treated with an optional hexacyanoferrate/
thiosulfate redox-based etching solution to dissolve extracellular particles, and processed for confocal imaging. 
(A) Confocal imaging of cells incubated with peptide-targeted vs. control AgNPs. Note robust uptake of PL3-
AgNPs (red) in NRP-1-positive PPC1 and U87-MG (and not NRP-1 negative M21) cells (high-magnification 
images are on the right of PL1-AgNP images). Control particles did not bind to the cells independent of their 
NRP-1 expression status. Scale bar: 20 µm (main images), and 2 µm (insets). (B) Quantitation of binding 
and internalization of CF555-labeled particles using ImageJ for samples from (A) and at least 3 independent 
experiments were carried out for individual conditions. Error bars: mean ± SD (N = 6), P-values were 
determined using unpaired Student’s t-test (ns, P > 0.05; ***p ≤ 0.001; ****p < 0.0001).
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with a mild biocompatible hexacyanoferrate/thiosulfate redox-based destain solution so that only internal-
ized AgNP signal remains30. In U87-MG and PPC1 cells, etching resulted in a modest decrease of the cellular 
PL3-AgNP signal (Figs. 2B, S13), suggesting that most of the cell-associated particles were internalized and pro-
tected from etching by cellular membrane. The uptake of PL3-AgNPs in U87-MG cells was NRP-1-dependent, 
as incubation with function-blocking anti-NRP-1 antibody abolished PL3-AgNP signal in U87-MG cells treated 
with an etching solution to remove extracellular AgNPs (Fig. S14). These experiments showed that PL3 peptide 
interacts with TNC-C and NRP-1 and that PL3-functionalized nanoparticles are taken up by NRP-1-positive 
cultured cells.
PL3-functionalized nanoparticles accumulate in malignant lesions. Systemic in vivo phage play-off 
studies showed that PL3 peptide-displaying phage outperforms other TNC-C binding candidate peptide phages 
in tumor homing. We next studied the effect of functionalization with synthetic PL3 peptide on in vivo tumor 
tropism of two classes of synthetic nanoparticles, iron oxide NWs and AgNPs.
We first tested the effect of PL3 functionalization on tumor homing of dextran-coated PEGylated paramag-
netic NWs – a dual-use model nanoplatform that can be used as a carrier for drugs and for MR imaging due to 
intrinsic T2 contrast properties8,26. NWs with an average size of 88.8 ± 5 nm and zeta potential of −7.8 ± 2 mV 
(Fig. S6) were coated with FAM-labeled PL3 peptide or FAM-Cys control with no significant effect on particle 
size or surface charge. NWs were i.v. administered at 7.5 mg/kg NWs in mice bearing prostate cancer xenografts 
(PC3 s.c. tumors), or gliomas (s.c. U87-MG and orthotopic WT-GBM), both known to overexpress TNC-C and 
NRP-18,27. After 5 h circulation, accumulation of PL3-NWs, but not control NWs, was observed in all 3 tumor 
models tested (Fig. 3A–C). Confocal analysis demonstrated that whereas the PL3-NW homing was mainly over-
lapping or associated with CD31-positive vascular structures (Fig. 3A–C, arrows), in some regions, the PL3-NWs 
extravasated and accumulated in the tumor parenchyma (Fig. 3A–C, arrowheads). In control organs, PL3-NWs 
and control NWs showed similar background (Fig. S7). Macroscopic imaging confirmed preferential tumor accu-
mulation of the PL3-NWs in U87-MG tumor mice (Fig. 4A,D). In tumor tissue PL3-NWs were found in the areas 
positive for TNC-C and NRP-1 immunoreactivities (Fig. 4B,C,E,F).
We also studied the binding of PL3 and control NWs to the clinical glioma. The NWs were overlaid on 
cryosections of GBM, washed, and subjected to confocal imaging. PL3-NWs showed co-localization with 
TNC-C-positive structures in tumor perivascular space and parenchyma (Figs. S8,9). For TNC-C detection we 
used an in-house monoclonal antibody, and as a specificity
We also tested the effect of PL3 coating on tumor homing of near-infrared dye-labeled AgNPs. Intravital imag-
ing with IVIS Spectrum after 5 h circulation showed that the PL3-CF647-AgNPs accumulated in U87-MG lesions 
at ~10 fold more than control CF647-AgNPs (Fig. 5A,B). Tumor homing of PL3-AgNPs was confirmed by confo-
cal imaging (Fig. 5C). Coadministration of PL3-AgNPs with blocking rabbit polyclonal antibodies against either 
TNC-C or NRP-1 resulted in a decrease in tumor homing, and a cocktail of both antibodies almost completely 
inhibited the tumor accumulation (Fig. 5C,D). These data show that PL3 functionalization results in specific 
tumor homing of different classes of nanoparticles.
PL3-guided proapoptotic NWs have anti-glioma activity. We next tested the effect of PL3- 
functionalization on anticancer efficacy of nanoparticles loaded with proapoptotic D(KLAKLAK)2 peptide. For 
these studies we used s.c. U87-MG tumor model in order to monitor tumor size, rather than survival, as the 
endpoint. Starting on day 36 after tumor induction (when the tumors had reached 100 mm3), the tumor mice 
were treated with i.v. PL3-D(KLAKLAK)2-NWs, D(KLAKLAK)2-NWs, PL3-NWs, or PBS for 10 injections every 
other day, and tumor volume and survival of the mice were recorded (Fig. 6A). Over the treatment, the vol-
ume of tumors in PBS, PL3-NW, and D(KLAKLAK)2 –NW-treated mice increased rapidly. In contrast, tumor 
growth in the D(KLAKLAK)2 -PL3-treated group was significantly delayed (Fig. 6B). The median survival of PBS, 
D(KLAKLAK)2-NW, PL3-NW, and PL3-D(KLAKLAK)2-NW groups was 55, 58, 54, and 70 days, respectively. 
In the D(KLAKLAK)2 -PL3 group, 50% of mice had prolonged survival compared to the animals in the other 
treatment groups (Figs. 6C and S11). Immunostaining of post-treatment tumor tissue with anti-CD31 antibody 
to visualize tumor vasculature showed that compared to controls PL3-D(KLAKLAK)2-NW-treated tumors had 
a significant reduction in CD31-positive area and cleaved Caspase-3 showed a significant increase in apoptotic 
cells (Figs. 6D, S12, S15).
Discussion
Most affinity-based precision delivery strategies target receptors on the surface of tumor cells. This approach, 
while clearly proven useful, has limitations, as it relies on targeting a limiting number of systemically acces-
sible receptors on genetically unstable malignant cells31. Compared to surface antigens on tumor cells, 
tumor-associated ECM represents an abundant and stable target with low shedding32. ECM directed affinity 
targeting strategies may allow simultaneous targeting of both malignant tumor cells and tumor support cells 
(fibroblasts, immune- and vascular cells) and be beneficial for improving treatment efficacies. TNC, an ECM 
component expressed at the invasive tumor front and in the angiomatrix, is predictive of adverse outcomes13 
and provides specific targeting opportunities due to precisely controlled expression of its multiple structurally 
and functionally different isoforms4,11. Here, we report the development of an affinity ligand, octameric PL3 
peptide, that targets C-domain of TNC and also interacts with NRP-1, a pleiotropic hub receptor upregulated 
in angiogenic sites and in malignant tissues involved in regulation of vascular permeability. Systemic PL3 phage 
nanoparticles and two types of synthetic PL3-guided nanocarriers home to solid tumors implanted in mice and 
bind to receptor-positive regions in clinical tumor samples. For therapeutic nanoparticles, PL3 functionalization 
improves their anticancer activity. Our study suggests potential uses for PL3 guided compounds and particles for 
improved detection and therapy of solid tumors.
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Over the years, several preclinical and clinical-stage affinity ligands for TNC have been developed, such as 
a aptamers33, FHK peptide7, a bispecific PL1 peptide that in addition to TNC-C also targets fibronectin extra 
domain B8, TNC-C-targeting single-chain G11 antibody34, and TNC-C/D targeting monoclonal antibody 81C635. 
These and other ECM-reactive affinity ligands have proven useful for tumor delivery of extracellularly-acting 
anticancer payloads such as cytokines/growth factors, or payloads with intrinsic internalizing ability, such as 
proapoptotic D(KLKLAK)2 peptide nanoparticles, or cell-permeable cytotoxic compounds3,32,36. However, a chal-
lenge for these and other ECM-directed systemic compounds is that they can only reach extravascular tumor 
tissue passively, through the increased leakiness of aberrant tumor microvasculature, a phenomenon known as 
enhanced permeability and retention (EPR) effect37. EPR shows extensive inter- and intratumoral variability, thus 
decreasing the utility of the EPR-based targeting strategies38. During systemic in vivo play-off experiments using 
a panel of phage clones derived from screen on recombinant TNC-C in tumor mice, we observed that a phage 
clone displaying PL3 peptide with C-terminal RLVR motif outperformed other phage clones that had shown 
better TNC-C binding under cell-free conditions. C-terminal RLVR of PL3 corresponds to RXXR CendR con-
sensus motif that, when exposed at the C-terminus, interacts with b1 domain of NRP-1 to trigger a trans-tissue 
pathway that mediates exit from the blood vessels and extravascular transport through tumor tissue23,39. Indeed, 
we observed specific binding of PL3 nanoparticles to recombinant NRP-1 b1b2 domain and not to b1b2 with 
Figure 3. Systemic PL3-NWs accumulate in solid tumors. PL3-NWs or control FAM-NWs were injected i.v. 
at 7.5 mg/kg into mice bearing s.c. U87-MG glioblastoma (A), orthotopic WT-GBM glioblastoma (B), or s.c. 
PC3 prostate carcinoma (C). Five h later, the animals were intracardially perfused with DMEM/BSA and the 
tumors and control organs were snap-frozen, sectioned, immunostained with rabbit anti-FAM (green) and 
rat anti-CD31 (red) antibodies, counterstained with DAPI (blue) and imaged by confocal microscopy. Arrows 
point to PL3-NWs in the CD31-positive vessels and arrowheads point to extravasated PL3-NWs in the tumor 
parenchyma. Insets: confocal images without DAPI channel. Bar charts: quantitation of homing of NWs by 
quantitative analysis of FAM fluorescence in tissue sections by Fiji ImageJ. Error bars: mean ± SEM (N = 3–6). 
Scale bars: 100 μm. P-values were calculated using unpaired Student’s t-test (ns p > 0.05; *p < 0.05; **p ≤ 0.01; 
***p ≤ 0.001).
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mutated CendR binding pocket, and binding and internalization of the PL3 nanoparticles in NRP-1-positive 
PPC1 cells and no interaction with NRP-1-negative M21 melanoma cells. In vivo, NPs, including biological bac-
teriophage nanoparticles, are because of their size particularly prone to be excluded from difficult-to-access parts 
of tumors, and PL3 functionalization may mitigate this problem. PL3 peptide functionalization results in a small 
reproducible increase in uptake of NWs in the liver. The liver, along with other organs of the reticuloendothelial 
system, plays a central role in the nonselective clearance of NPs, primarily due to scavenger and phagocytic func-
tions of liver Kupffer cells40,41. PL3-dependent increase in liver accumulation may be due to NRP-1 binding-ability 
of the peptide, as NRP1 has been detected in hepatic stellate cells and liver sinusoidal endothelial cells42,43. A 
potential strategy to mitigate NRP-1-dependent accumulation of PL3-targeted compounds in nontarget organs 
may be to render its CendR motif proteolytically activatable, as we have done with urokinase dependent uCendR3 
peptide44. Numerous studies document the ability of CendR peptides to specifically increase the accumulation 
of a variety of anticancer therapeutics, such as chemotherapeutic agents, antibodies and NPs, in tumors45–51. 
For PL3 peptide, combination of CendR activity with the tumor ECM homing function may increase acces-
sibility of TNC-C deeper in tumor parenchyma than would be possible under the conditions of physiological 
EPR with simple docking-based affinity targeting. In 2016, a chimeric 19-mer chimeric peptide composed of 
TNC-A-D domain binding peptide and tLyP-1 tumor penetrating peptide52 that targets NRP-1 on tumor cells 
was reported to allow anti-glioma drug delivery via NRP-1- and TNC-mediated specific penetration of nano-
particles into glioma parenchyma53. Compared to that peptide, the 8-amino acid PL3 peptide we have identified 
has the advantage of being smaller, and hence less likely to be immunogenic and simpler to produce and develop 
towards clinical applications. In both these peptides, the CendR motif is C-terminally exposed and does not need 
on-site proteolytic activation, as seen for several other tumor penetrating peptides. NRP-1 is expressed in the 
Figure 4. PL3-NWs in tumor localize at areas positive for TNC-C and NRP1 immunoreactivities. PL3-NWs 
(A–C, upper row), or control NWs (D–F, lower row) were i.v.-administered at 7.5 mg/kg into mice bearing 
s.c. U87-MG glioblastoma. Five h later, the animals were intracardially perfused with DMEM, and tissues 
were collected for ex vivo macroscopic imaging and fluorescence microscopy. (A,D) Ex vivo macroscopic 
Illumatool imaging of PL3 and control NWs in green channel. Tu: tumor; Br: brain, Ki: kidney; Spl: spleen; 
Li: liver; Lu: lung; He: heart. The images are representative of 3 independent experiments. (B,C,E,F) Confocal 
imaging of NWs, TNC-C, and NRP-1 in tumor cryosections. PL3-NWs colocalize with perivascular TNC-C 
and NRP1 (arrows), whereas FAM-NWs show only background accumulation. Tumor tissues were stained with 
rabbit anti-FAM (green), anti-TNC-C ScFv G11 (red), and rabbit anti-NRP1 (red) antibodies. Arrows point 
to colocalization of PL3-NW with TNC-C and NRP1. Scale bar, 100 µm. The images are representative of 3 
independent experiments.
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endothelial cells in non-malignant sites, albeit at lower levels than observed in tumors, and systemic peptides with 
C-terminally exposed CendR motif show increased background, in particular in first-met vascular beds, lung, 
and heart23,52. We have reported on development of tumor penetrating peptides containing cryptic CendR motifs 
that are cleavage-activated by a tumor-associated serine protease, urokinase-type plasminogen activator for 
tumor-specific extravasation and tissue penetration44,54. Our ongoing studies will explore homing and activation 
of PL3-derived cryptic CendR peptides with added C-terminal residues compatible with CendR motif activation 
of the peptide in tumor microenvironment. We hypothesize that this strategy may add additional layer of tumor 
selectivity to further improve the tumor homing/background ratio for PL3 and other ECM-targeted peptides.
The mode of interaction of PL3 peptide with TNC-C remains to be determined in follow-up studies. At neu-
tral pH, the net charge of PL3 peptide is +3, whereas TNC-C is negatively charged (−5). Whereas electrostatic 
interactions may contribute to peptide-receptor interaction, the binding is likely to involve other mechanisms 
also, as no binding of PL3 phage was observed to Fn-EDB (charge −10 at pH 7). Ongoing in silico modeling com-
bined with site-directed mutagenesis studies will map the binding site of PL3 on TNC-C. This information can 
Figure 5. Systemic PL3-AgNPs home to U87-MG tumors. (A) In vivo imaging of U87-MG s.c. tumor-bearing 
mice injected with Alexa-647-labeled PL3-AgNPs (upper row), or with non-targeted AgNPs (lower row). 
The fluorescence imaging was performed using IVIS Lumina Imaging System at pre-injection and at 5 h post-
injection. Three mice per group were i.v. injected with AgNPs; images after spectral un-mixing are shown. Note 
elevated tumor Alexa-647 signal in mice injected with PL3-AgNPs at 5 h post-injection. (B) Quantification of 
tumor Alexa-647AgNP fluorescence at pre-injection and at 5 h time points. The signal is expressed as Average 
Radiant Efficiency [p/s]/[µW/cm²]. Error bars: mean ± SEM (N = 3); P-values were determined using two-way 
ANOVA Fisher’s LSD test (ns, P > 0.05; ****P ≤ 0.0001). (C) The PL3-AgNP green signal was quantified from 
representative images using Fiji ImageJ. Error bars, mean ± SEM (N = 3 mice per group); scale bars: 20 μm; 
p-value was determined using Student unpaired t-test, two-tailed; ***p ≤ 0.001; ****p < 0.0001. (D) Effect of 
TNC-C and NRP-1 antibodies on tumor accumulation of PL3-AgNPs. PL3-AgNPs alone, or in combination 
with anti-TNC-C or anti-NRP1 antibodies, or a cocktail of both antibodies were i.v injected into mice bearing 
U87-MG xenograft tumors. Mice were perfused through the heart with PBS/DMEM 5 h after injection and 
organs were collected for cryosectioning and confocal microscopy. Colors: PL3-AgNPs (green), CD31-positive 
blood vessels (red) and DAPI (blue).control, we confirmed that preincubation of the antibody with recombinant 
TNC-C resulted in reduced staining (Fig. S10).
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be used to develop PL3 derivatives containing non-natural amino acids or low molecular weight peptidomimetic 
compounds of improved binding and plasma stability.
In summary, this study describes the identification of an 8-amino acid homing peptide, PL3, that interacts 
with TNC-C and with the cell- and tissue penetration receptor NRP-1. Systemic PL3-guided nanoparticles accu-
mulated in tumor xenografts implanted in mice. The PL3-guided nanoparticles were useful for tumor detection, 
imaging and served as a tumor-seeking carrier for a proapoptotic peptide anticancer payload. Our study warrants 
future studies to study applications for PL3-targeted compounds and nanoparticles for improved detection and 
therapy of solid tumors.
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